Our newly established testing laboratory in Berlin which supports the fight against the Corona virus is already running: In the lab, our employees – more than 140 have volunteered – are able to conduct up to 1,000 additional SARS-CoV-2 tests per day. This helps to slow down the spread of the virus as fewer infections remain undetected and infection chains can be better reconstructed.
When the news of the coronavirus first emerged, Gilead immediately began to investigate the potential of remdesivir, a medicine we had been studying for many years as part of our extensive research in antivirals. Remdesivir had never been approved for use but based on what we had learned to date, we knew it might have potential with the novel coronavirus. Since then, we have been working with the greatest sense of urgency and responsibility to determine whether remdesivir does indeed work against COVID-19.
Medtronic Care Management Services offers new solutions to help evaluate and monitor patients for COVID-19
As health systems cope with a growing onslaught of COVID-19 cases, clinicians need new ways to evaluate and monitor symptoms of patients who have been exposed to or diagnosed with the disease without putting themselves, or others, at risk.
For 20 years, Medtronic Care Management Services (MCMS) has offered a suite of remote monitoring solutions for hospitals, health plans, and home health agencies, primarily to help patients manage complex, chronic, co-morbid conditions like heart failure or diabetes.
Amid a global pandemic, employees band together to power ventilator production.
Philomena Flaherty had a feeling she would play a role in the global effort to mobilize against COVID-19.
Flaherty works at a Medtronic facility in Galway, Ireland, where she makes a key component of the company’s high-performance Puritan Bennett™ 980 ventilator. When COVID-19 started spreading in China, Flaherty realized demand for the devices she has made for years would soon surge. “I always knew it would come to our door,” she said.
April 1, 2020 /3BL Media/ - Medtronic plc (NYSE:MDT), the global leader in medical technology, continues to make progress in increasing ventilator production worldwide. The company has increased production by more than 40 percent to date and is on track to more than double its capacity to manufacture and supply ventilators in response to the urgent needs of patients and healthcare systems across the globe confronting COVID-19.
Researchers at three institutions in the U.S. and U.K. receive grants to advance studies of repurposed drugs and novel antibodies in preventing COVID-19
PURCHASE, NY – March 31, 2020 /3BL Media/ – The partners in the COVID-19 Therapeutics Accelerator have announced grants of $20 million to three institutions—the University of Washington, University of Oxford, and La Jolla Institute for Immunology—to fund clinical trials in order to identify highly potent immunotherapies for the COVID-19 pandemic.
The company's Chief Global Supply Chain Officer shares the measures the company has taken to maintain its supply chain operations during the current novel coronavirus outbreak.
The effects of the global Covid-19 pandemic are undeniable.
As the world rapidly learns to adapt to an ever-changing landscape, Johnson & Johnson's supply chain, which produces everything from contact lenses to prescription medications to fever reducers, is currently holding steady and meeting patient needs.
As SARS-CoV-2 moves fast through our global population, the pharmaceutical industry faces tremendous pressure to move even faster.
March, 2020 - /3BL Media/ - Industry leaders are jousting with questions of how to quickly evaluate new and repurposed drugs while simultaneously readying their operations for rapid transformation. Novel partnerships between private R&D teams and public health agencies are emerging to address the “discovery” half of that equation, which leaves company leaders to grapple with the other half: how can they prepare their operations for commercial-scale manufacturing of a therapy that hasn’t yet been identified or approved?
Despite the unprecedented advances in healthcare, the benefits of progress are not being shared equally among all populations. Many treatments and services that have become the standard of care in some areas remain inaccessible to others. The result is inequality in diagnosis and treatment — and most importantly, in health outcomes — for the most prevalent diseases.
Employees and Employers Empowered with No-Cost Educational Resources Addressing Opioid Misuse Prevention
SILVER SPRING, Md., March 5, 2020 /3BL Media/ – The Operation Prevention program, created in partnership with the Drug Enforcement Administration (DEA) and Discovery Education, today announced a four-part digital module series to educate workplace professionals about the opioid epidemic and provide resources for prevention.